Last reviewed · How we verify
NCT04720781
The Need of Revisiting to an Outpatient Clinic After the Prescription of Vonoprazan or Esomeprazole
NA trial testing Vonoprazan in Gastroesophageal Reflux in 300 participants. Completed in 31 December 2024.
31 December 2024
Quick facts
| Lead sponsor | Showa Inan General Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 300 |
| Start date | 21 January 2021 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- Vonoprazan — full drug profile →
- Esomeprazole (esomeprazole) — full drug profile →
Conditions studied
- Gastroesophageal Reflux — all drugs for Gastroesophageal Reflux →
Sponsor
Showa Inan General Hospital
Who can join
Adults 19 to 100, any sex, with Gastroesophageal Reflux. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
After vonoprazan (20mg/day) or esomeprazole (20mg/day) for 4weeks is prescribed for patients with erosive esophagitis diagnosed by esophagogastroduodenoscopy, the number of patients who will visit our outpatient clinic again due to some reasons without any appointments is compared with vonoprazan group and esomeprazole.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04720781
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Vonoprazan
Trials testing the same drug.
- NCT06953986 — A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA · NA · recruiting
- NCT06955520 — Vonaprazan Versus Esomeprazole for Healing of LA Grade B or Higher Esophagitis After POEM · NA · recruiting
- NCT07068607 — Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradicatio · Phase 4 · recruiting
- NCT07242456 — Head-to-head Study of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID vs. Vonoprazan 20 mg BID Plus Amoxicillin 1 g TID fo · Phase 2, PHASE3 · recruiting
- NCT06811207 — Comparison of the Efficacies of Two Novel Dose Dual Therapies in the First-line Helicobacter Pylori Eradication · Phase 3 · unknown
Other recruiting trials for Gastroesophageal Reflux
Currently open trials in the same condition.
- NCT07291700 — Study on Hydrotalcite for Relief of Acid Symptoms Due to Acid Rebound After Stopping Long-Term PPI Therapy · recruiting
- NCT06255886 — Treatment of Gastroesophageal Reflux Disease in Infants · Phase 4 · recruiting
- NCT06534359 — Transpyloric Versus Gastric Feeding in Bronchopulmonary Dysplasia · NA · recruiting
- NCT06687603 — Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms · NA · recruiting
- NCT06339801 — Role of Mucosal Impedance Measurement for the Diagnosis of Gastroesophageal Reflux Disease · recruiting
Other Showa Inan General Hospital trials
Trials by the same sponsor.
- NCT07243639 — Efficacy and Safety of Etrasimod in Elderly Patients With Ulcerative Colitis · NA · recruiting
- NCT06626165 — Association Between Effectiveness of Mirikizumab and UC Patients With High Neutrophilic Infiltration in Epithelium of th · Phase 4 · completed
- NCT06372613 — Association Between LRG and Histologic Remission in Ulcerative Colitis · recruiting
- NCT05930041 — Injured Submucosal Arteries After CSP for 10-19 mm Nonpedunculated Colorectal Polyps. · NA · completed
- NCT05213208 — Safety of Propofol Sedation ( > 200 mg) for Colonoscopy. · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04720781 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Showa Inan General Hospital
- Last refreshed: 18 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04720781.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing